Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Firms Up Cost-Effectiveness Plans As Industry Concerns Linger

Japan firms up proposals for expanded cost-effectiveness assessment scheme for selected drugs and devices after a policy committee outlines plans that could see associated price adjustments for reviewed products.

Japan Health Technology Assessment Cost Effectiveness

Korea’s Clinical Trial Road Map Eyes Faster Development, Patient Safety, Rare Diseases

Amid fierce jostling among Asian countries to attract clinical research, South Korea unveils a five-year road map to accelerate trial activities and improve global competitiveness, focusing on expansion of opportunities for rare and intractable diseases, protection of subjects' rights and enhancement of new drug development capabilities.

South Korea Clinical Trials Policy

China Tightens Clinical Trial Oversight Post Gene-Edited Babies Scandal

New draft regulation will require state-level approval over high-risk and reproductive use of gene and cell technologies.

China Clinical Trials Regulation

A Wild CAR-T Race In China: The Hype, Reality And What Works

As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.

China Clinical Trials Research & Development